What is Haemonetics's cash received from option exercises?

Haemonetics (HAE) reported cash received from option exercises of $1.15M in Q4 2025.

How has Haemonetics's cash received from option exercises changed year-over-year?

Haemonetics's cash received from option exercises increased by 127.1% year-over-year, from $505K to $1.15M.

What is the long-term trend for Haemonetics's cash received from option exercises?

Over 2 years (2022 to 2024), Haemonetics's cash received from option exercises has grown at a -17.0% compound annual growth rate (CAGR), from $2.34M to $1.61M.

Haemonetics HAE Cash received from option exercises

Cash received from option exercises at other companies

RepligenRGEN

$0-100%

ADMA BiologicsADMA

$588K+482%

RevvityRVTY

——

Other financials

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

See full

Market cap$3.31B-18.0%

Profitability

See full

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's cash received from option exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Haemonetics's cash received from option exercises?: Haemonetics (HAE) reported cash received from option exercises of $1.15M in Q4 2025.
How has Haemonetics's cash received from option exercises changed year-over-year?: Haemonetics's cash received from option exercises increased by 127.1% year-over-year, from $505K to $1.15M.
What is the long-term trend for Haemonetics's cash received from option exercises?: Over 2 years (2022 to 2024), Haemonetics's cash received from option exercises has grown at a -17.0% compound annual growth rate (CAGR), from $2.34M to $1.61M.